Clinical Trials Browser

Ovarian Neoplasms

Endometrial Neoplasms

Advanced Breast Cancer

Fallopian Tube Neoplasms, Ovarian Neoplasms

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma Of Esophagus

Breast Neoplasms

Triple Negative Breast Neoplasms

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Carcinoma, Non-Small-Cell Lung

Ovarian Neoplasms

Pancreatic Cystic Neoplasm

Esophageal Squamous Cell Carcinoma

Lung Diseases, Interstitial

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Triple Negative Breast Neoplasms

Stomach Neoplasms

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Breast Neoplasms

Advanced Squamous Non-Small Cell Lung Cancer

Ovarian Neoplasms

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Mouth Neoplasms

Ovarian Neoplasms

AIDS-related Kaposi sarcoma, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

Squamous Non-small Cell Lung Cancer

Carcinoma, Squamous Cell

Multiple Myeloma, Triple Negative Breast Neoplasms

Gastric Cancer Peritoneal Metastases

Carcinoma, Non-Small-Cell Lung, Neoplasms, Disease Progression

Esophageal Neoplasms

Pancreatic Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

PDAC - Pancreatic Ductal Adenocarcinoma

Stomach Neoplasms

Uterine Cervical Neoplasms, Drug Hypersensitivity, Ovarian Neoplasms, Endometrial Neoplasms

Stage III and IV Ovarian Cancer

Esophageal Neoplasms

Pancreatic Intraductal Neoplasms

Esophageal Neoplasms, Stomach Neoplasms

Uterine Cervical Neoplasms

Platinum-Resistant Primary Peritoneal Carcinoma

Triple Negative Breast Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Clinical Trials

A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

Metronomic Oral Paclitaxel Monotherapy and Combined Immunotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose Exploration and Expansion Trial

RAINFOL-02

Oral Paclitaxel as Neoadjuvant Therapy in Elderly NSCLC: A Phase II Trial

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer

MIGRANT

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

RAINFOL™-07

ERASE-Chemo

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

SYS6090 Combination Therapy in Advanced Lung Cancer

ALISCA-Lung2

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

CECYDE

Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer

NeoCamre-HN

The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

HYPERBOLIC

MRD2START

Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer

The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel

Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

PANORAMIX

Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer

The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC

JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC

Feasibility Trial of EUS-PCA in IPMN Pancreatic Cysts

Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma

Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer

Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer